central diabetes insipidus
Conditions
Brief summary
Trait anxiety level and correct classifications of facial & body expression after 28 (+/-2) days of treatment assessed with the STAI-T and the EmBody/EmFace Task. ▪ The STAI-T comprises 20 items scoring 1-4 points each. ▪ The EmBody/EmFace comprises 84 items scoring correct or incorrect each.
Detailed description
Emotion recognition and empathy, Hormonal and subjective response to psychological stress, Amygdala and subjective response in the functional MRI scan, Further psychological outcomes, Metabolic outcomes, Objective assessment of a close third person, Safety outcome
Interventions
DRUGOXYTOCIN
DRUGThe placebo nasal spray will be identical in volume
DRUGlabelling but not
container system
DRUGand other features. The placebo will contain 0.9%
sodium chloride and no OXT.
Sponsors
Universitaetsspital Basel
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Trait anxiety level and correct classifications of facial & body expression after 28 (+/-2) days of treatment assessed with the STAI-T and the EmBody/EmFace Task. ▪ The STAI-T comprises 20 items scoring 1-4 points each. ▪ The EmBody/EmFace comprises 84 items scoring correct or incorrect each. | — |
Secondary
| Measure | Time frame |
|---|---|
| Emotion recognition and empathy, Hormonal and subjective response to psychological stress, Amygdala and subjective response in the functional MRI scan, Further psychological outcomes, Metabolic outcomes, Objective assessment of a close third person, Safety outcome | — |
Countries
Germany, Netherlands
Outcome results
None listed